Search News & Articles
Today
Today
  • Regulatory NewsRegulatory News

    CDRH, MDIC Look to Global Application for NEST

    • 24 September 2018
    With the first version of the National Evaluation System for health Technology (NEST) set to open for business by the end of 2019, the shared vision among management at the US Food and Drug Administration (FDA) has expanded to a global scope.
  • Regulatory NewsRegulatory News

    FDA Finalizes Guidance on Benefit-Risk Factors for 510(k)s

    • 24 September 2018
    The US Food and Drug Administration (FDA) on Monday finalized guidance on evaluating the benefit-risk profile of medical devices submitted under the 510(k) pathway that have the same indication as their predicate devices but have different technological characteristics and benefit-risk profiles.
  • Regulatory NewsRegulatory News

    Phase 3 Trial Costs Estimated at $19M, Study Finds

    • 24 September 2018
    The cost of a Phase III clinical trial ranges widely, though a new study pegs the median cost of 138 clinical trials in 2015 and 2016 at $19 million.
  • Regulatory NewsRegulatory News

    Researchers Point to R&D Treaty to Spur New Infectious Disease Treatments

    • 24 September 2018
    As current incentives to promote the development of new infectious disease treatments have yet to reach their potential, researchers in a new Food and Drug Law Journal paper suggest forming a research and development treaty.
     
  • FEATURED STORY
    Story Thumbnail
    Feature ArticlesFeature Articles

    Complying With the new EU IVDR

    • 22 August 2018

    This article discusses processes and plans that need to be developed by In Vitro Diagnostic (IVD) companies to address the new EU In Vitro Diagnostic Regulations (IVDRs) in advance of their coming into full force in 2022.

  • Regulatory NewsRegulatory News

    Brexit-Related Medicine Supply Disruptions: EMA Revises List

    • 24 September 2018
    The European Medicines Agency (EMA) on Monday announced that the number of centrally authorized medicines (CAPs) for which there are Brexit-related supply disruption concerns has declined from 108 to 39 (25 human medicines and 14 veterinary medicines).
     
  • Regulatory NewsRegulatory News

    EMA Extends Valsartan Review to Include Four More Active Substances

    • 21 September 2018
    The European Medicines Agency (EMA) announced Friday it has extended its review of two impurities classified as probable human carcinogens from its initial valsartan focus to include medicines containing four other “sartans.”
  • Regulatory NewsRegulatory News

    DITTA Calls on FDA, Health Canada to Take Up Proposed IMDRF Work on Cybersecurity

    • 21 September 2018
    A new work item on cybersecurity was proposed at the International Medical Device Regulators Forum (IMDRF) management committee hearing this week in Beijing, China by the Global Diagnostic Imaging, Healthcare IT & Radiation Therapy Trade Association (DITTA).
  • Regulatory NewsRegulatory News

    CHMP Backs 13 New Medicines, Maintains Negative Opinion of Sarepta’s Exondys

    • 21 September 2018
    The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) on Friday recommended thirteen new medicines for EU approval and reaffirmed its negative opinion of Sarepta Therapeutics’ Duchenne muscular dystrophy drug Exondys (eteplirsen).

Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe

Most Viewed Articles

Regulatory Focus ArticlesRSS 2.0
Recon
Recon: Amarin’s Fish Oil Drug Cut Heart Risks by 25% in Ph. III Study
24 September 2018
Welcome to Regulatory Reconnaissance, your daily regulatory news and intelligence briefing.
Recon: Medtronic to Acquire Mazor Robotics for $1.6B; Dozens Lose Sight After Being Injected with Compounded Eye Drug Recon: Amicus Buys Celenex Gene Therapy Portfolio for $100M; EU Approves 5th Humira Biosimilar Recon: Gilead, Galapagos Report Positive Phase III Results for RA Drug Filgotinib
Regulatory News
CDRH, MDIC Look to Global Application for NEST
24 September 2018
With the first version of the National Evaluation System for health Technology (NEST) set to open for business by the end of 2019, the shared vision among management at the US Food and Drug Administration (FDA) has expanded to a global scope.
FDA Finalizes Guidance on Benefit-Risk Factors for 510(k)s Phase 3 Trial Costs Estimated at $19M, Study Finds Researchers Point to R&D Treaty to Spur New Infectious Disease Treatments
Feature Articles
Clarifying FDA’s Off-Label Promotion Efforts
19 September 2018

This article discusses off-label promotions and subsequent changes in related FDA guidances derived from the agency’s approaches to two First Amendment cases and recently enacted state laws regarding off-label communication. 

Clarifying FDA’s Off-Label Promotion Efforts Canadian Drug Advertising Regulations Pregnancy and Lactation Labeling Rule: Strategies for Updating Prescription Drug Labels for Compliance
Explainers
Regulatory Explainer: Everything You Need to Know About FDA’s Priority Review Vouchers
23 August 2018
Since 2007, the US Food and Drug Administration (FDA) has issued a handful of special "priority review" vouchers which allow its recipient to expedite the review of any one of its new drug products. What are these vouchers, why is FDA issuing them and what benefit might they have for society? Find out in our latest Regulatory Explainer on the Priority Review Voucher system.
Regulatory Explainer: Everything You Need to Know About Biosimilars Regulatory Explainer: FDA User Fee Reauthorizations From 2018 to 2022 Regulatory Explainer: 21st Century Cures Redux and What it Will Mean for FDA
About Regulatory Focus

Regulatory Focus is the flagship online publication of the Regulatory Affairs Professionals Society (RAPS), the largest global organization of and for those involved with the regulation of healthcare and related products, including medical devices, pharmaceuticals, biologics and nutritional products.

RAPS' Latest
Medical Device Validation: What You Need to Know and Why It's Important
23 August 2018
Inadequate process validation for medical devices is one of the most common issues leading to warnings from FDA. It may also be the most difficult to address, according to Max Sherman, the editor of RAPS’ recently published second edition of The Medical Device Validation Handbook, but regulatory professionals need a better understanding of device validation as it has become increasingly important.
Risk Management: What Regulatory Professionals Need to Know Top Latin American Officials to Examine Region’s Regulatory Challenges and Opportunities at RAPS Regulatory Convergence How to Prepare for the RAC Exam
Latest Tweets